Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10301828" target="_blank" >RIV/00216208:11110/15:10301828 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/15:00086570 RIV/00216208:11150/15:10301828 RIV/00216208:11120/15:43909772 RIV/61989592:15110/15:33156954 and 4 more

Result on the web

<a href="http://dx.doi.org/10.1159/000381327" target="_blank" >http://dx.doi.org/10.1159/000381327</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1159/000381327" target="_blank" >10.1159/000381327</a>

Result language

angličtina

Original language name

Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?

Original language description

Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first-or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remainedalive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent. Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse. (C) 2015 S. Karger AG, Basel

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Acta Haematologica

ISSN

0001-5792

e-ISSN

—

Volume of the periodical

134

Issue of the periodical within the volume

3

Country of publishing house

CH - SWITZERLAND

Number of pages

6

Pages from-to

187-192

UT code for WoS article

000361636000012

EID of the result in the Scopus database

2-s2.0-84930252027